Needham Remains Positive on Gilead Sciences, Inc. Following Clinical Results From Multiple HCV Programs

April 27, 2015 4:16 PM

8 0

In a research report issued today, Needham analyst Alan Carr reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) with a $120 price target, after the company reported results from several Phase 2 clinical studies evaluating investigational uses of Harvoni® and other Sovaldi®-based regimens for the treatment of chronic hepatitis C virus (HCV) infection in patients with advanced liver disease, including patients with decompensated cirrhosis, patients with fibrosing cholestatic hepatitis C and patients with portal hypertension.

Carr wrote, “Gilead presented results from multiple HCV programs at the EASL meeting. Of interest were results from a Phase 2 trial evaluating 4- and 6- wk tx w/sofosbuvir/GS-5816/GS-9857 in GT1 pts. Efficacy was generally encouraging in tx-naive pts treated for 6-wks (SVR12 non-cirrhotic 14/15; cir...

Read more

To category page